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Abstract: Autoinflammation has recently been suggested in the
pathogenesis of neutrophilic dermatoses but systematic studies on their
cytokine profile are lacking. Notably, amicrobial pustulosis of the folds
(APF), classified among neutrophilic dermatoses, has been studied only
in small case series.
In our University Hospital, we conducted an observational study on
15 APF patients, analyzing their clinical and laboratory features with a
follow-up of 9 months to 20 years. Skin cytokine pattern of 9 of them
was compared to that of 6 normal controls.
In all patients, primary lesions were pustules symmetrically invol-
ving the skin folds and anogenital region with a chronic-relapsing course
and responding to corticosteroids. Dapsone, cyclosporine, and tumor
necrosis factor blockers were effective in refractory cases. In skin
samples, the expressions of interleukin (IL)-1b, pivotal cytokine in
autoinflammation, and its receptors I and II were significantly higher in
APF (P¼ 0.005, 0.018, and 0.034, respectively) than in controls.
Chemokines responsible for neutrophil recruitment such as IL-8
(P¼ 0.003), CXCL 1/2/3 (C-X-C motif ligand 1/2/3) (P¼ 0.010),
CXCL 16 (P¼ 0.045), and RANTES (regulated on activation, normal
T cell expressed and secreted) (P¼ 0.034) were overexpressed. Mol-
ecules involved in tissue damage like matrix metalloproteinase-2
(MMP-2) (P¼ 0.010) and MMP-9 (P¼ 0.003) were increased.
APF is a pustular neutrophilic dermatosiswith a typical distribution in
all patients. The disorder may coexist with an underlying autoimmune/
dysimmune disease but is often associated only with a few autoantibodiesvecchio, MD, Emil
Massimo Cugno, MD
(Medicine 94(50):e2301)
Abbreviations: ANA = antinuclear antibodies, APF = amicrobial
pustulosis of the folds, BCA = bicinchoninic acid, CXCL = C-X-C
motif ligand, IBD = inflammatory bowel diseases, IL = interleukin, IL-
1R = interleukin 1 receptor, MMP = matrix metalloproteinase, PG =
pyoderma gangrenosum, RANTES = regulated on activation, normal T
cell expressed and secreted, RIPA = radioimmunoprecipitation assay,
Siglec = sialic acid-binding immunoglobulin-type lectin, SS = Sweet
syndrome, TIMP = tissue inhibitor of metalloproteinase, TNF = tumor
necrosis factor, TNFR = tumor necrosis factor receptor.
INTRODUCTION
Amicrobial pustulosis of the folds (APF) is a rare chronic-relapsing neutrophilic dermatosis that affects almost exclu-
sively young women with sudden onset of sterile pustular
lesions involving the major cutaneous folds, anogenital area
and scalp as well as minor skin folds, particularly the area
around the nostrils, retroauricular regions, and external auditory
canals.1–4 Its histological picture is characterized by subcorneal
pustules associated with a predominantly neutrophilic infiltrate
in the dermis, which lead to include APF within the spectrum of
neutrophilic dermatoses.4,5 Neutrophilic dermatoses represent a
clinically heterogeneous group of disorders hallmarked by an
accumulation of neutrophils in the skin and rarely internal
organs.6 Recently, pyoderma gangrenosum (PG) and Sweet
syndrome (SS), the 2 prototypic neutrophilic dermatoses, have
been included among the autoinflammatory diseases,7 which
are characterized by recurrent episodes of sterile inflammation
in the affected organs, including the skin, without circulating
autoantibodies and autoreactive T cells.8 In PG and SS, we
recently demonstrated an overexpression of cytokines/chemo-
kines and molecules amplifying the inflammatory network,
supporting the view that these disorders are autoinflammatory
in origin.9 Here, we analyze the clinical picture, histopatholo-
gical aspects, course, and treatment of the largest series of APF
patients to date. Moreover, to support the inclusion of APF
within the spectrum of autoinflammatory diseases, we con-
ducted the first systematic study evaluating the cytokine expres-
sion profile in the lesional skin of APF by means of a protein
array method.
PATIENTS AND METHODS
Patients
Fifteen patients seen in our University Department fromwere studied clinicopathologically and
patients were followed-up for a period
to 20 years. The diagnosis of APF was
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established on the basis of criteria previously suggested by some
of us3 and slightly modified considering the presence of 3 major
criteria and at least 1 minor criterion. Briefly, major criteria
include: pustulosis involving 1 or more major folds, 1 or more
minor folds and the anogenital area; histological pattern con-
sisting of intraepidermal spongiform pustules and a mainly
neutrophilic dermal infiltrate; negative culture from unopened
pustule. Minor criteria include: association with 1 or more
autoimmune or autoinflammatory disorders; positive antinuc-
lear antibodies (ANA) at a titer of 1/160 or higher; presence of 1
or more serum autoantibodies. To conduct the immunological
study, lesional skin biopsies, taken from 9 out of 15 patients,
were evaluated by means of a cytokine array method. All the 9
patients were not receiving any treatment; in particular, previous
systemic antibiotic therapies had been discontinued due to their
inefficacy.
As controls, we used normal skin tissue specimens adja-
cent to benign skin tumors, namely melanocytic nevi localized
to the trunk (periflexural areas), taken from 6 subjects (5 women
and 1 man; age range: 20–38 years) who underwent excision of
the benign lesion. These control subjects were otherwise healthy
and in particular were not suffering from any immune-
mediated disorder.
Blood and tissue samples were collected during routine
diagnostic procedures and all patients gave oral informed
consent that remaining samples could be used for research
Marzano et alpurposes. The protocol was approved by the Institutional
Review Board of IRCCS Fondazione Ca’ Granda, Ospedale
Maggiore Policlinico, Milano, Italy.
METHODS
Cytokine Array
Cytokine array was performed on frozen skin specimens as
previously decribed.9 Briefly, frozen skin tissue samples were
reduced into thin slices and then thawed in RIPA (radioimmu-
noprecipitation assay) buffer (3mL of buffer per gram of tissue).
The samples were centrifuged twice at 48C and the supernatant
of each sample, representing the total cell lysate, was collected.
Total protein content in each sample was measured, and, for
each sample, a volume containing 100mg of proteins was
loaded in a glass-slide format of cytokine antibody array
(RayBio1, Norcross, GA). The results were expressed as
numerical data obtained by the conversion of fluorescent signals
using a data extraction software. The molecules tested were the
following: interleukin 1 beta (IL-1 beta); interleukin 1 receptor I
(IL-1RI), and IL-1RII; tumor necrosis factor alpha (TNF-
alpha); tumor necrosis factor receptor I (TNFRI) and TNFRII;
interleukin 17 (IL-17); interleukin 17 receptor (IL-17R); leu-
kocyte selectin (L-selectin); interleukin 8 (IL-8); regulated on
activation, normal T cell expressed and secreted (RANTES);
CXCL 1,2,3 ([C-X-C motif] chemokine ligand 1,2,3;
[C¼ cysteine, X¼ any amino acid]); CXCL 16 ([C-X-C motif]
chemokine ligand 16); matrix metalloproteinase-2 (MMP-2)
and MMP-9; tissue inhibitor of metalloproteinase 1 (TIMP-1)
and TIMP-2; sialic acid-binding immunoglobulin-type lectin 5
(Siglec 5) and Siglec 9.
Statistics
The data are shown as median values and interquartileranges (25th and 75th percentiles). The between-group differ-
ences were analyzed using Mann–Whitney nonparametric tests
for independent samples. The significance level was set at
2 | www.md-journal.comP< 0.05. The data were analyzed using the SPSS PC statistical
package, version 22.00 (IBM SPSS Inc., Chicago, IL).
RESULTS
Clinical Features
Clinical features are reported in Table 1. All but 2 patients
were female with an age ranging from 11 to 43 years (median 28
years) and a duration of disease ranging from 9 months to 30
years (median 5 years). In 8 patients, APF presented with an
associated autoimmune/autoinflammatory condition, namely
systemic lupus erythematosus (1 patient), subacute cutaneous
lupus erythematosus (1 patient), systemic lupus erythematosus/
scleroderma overlap syndrome (1 patient), celiac disease (1
patient), antiphospholipid syndrome (1 patient), and inflamma-
tory bowel diseases (3 patients); these last 3 cases were trig-
gered by tumor necrosis factor-alpha blockers. The other 7 cases
were idiopathic and 1 of them, at disease onset, had a pulmonary
infiltrate which was unresponsive to systemic antibiotics and
resolved only after systemic corticosteroids.
In all the patients, the skin lesions were multiple-erythe-
matous pustules coalescing in macerated erosive areas
(Figure 1), symmetrically involving the major skin folds, such
as groins (Figure 1A) and axillae (Figure 1C), and the anogen-
ital region (Figure 1A and B) as well as minor folds such as the
angle of the mouth (Figure 1D), external auditory canals,
retroauricular flexures (Figure 1E), and the area around the
nostrils; the lesions were associated with intense oozing and
accompanied by burning.
Laboratory Findings
On admission to our department, all patients showed an
increase in the erythrocyte sedimentation (ranging from 60mm/
1st h to 100mm/1st h) and in serum levels of C reactive protein
(ranging from 1.25 to 6.2mg/dL; normal values< 0.5mg/dL).
Case 7 showed also mild anemia (hemoglobin: 11.4 g/dL). ANA
and various other serum autoantibodies were present in 13
patients (Table 1). Repeated bacteriological cultures from
closed pustules were negative, while cultures from erosive
areas demonstrated the presence of Staphylococcus aureus in
all patients. Fungal cultures were negative in all patients.
Histopathological Aspects and Direct/Indirect
Immunofluorescence Findings
In all patients, biopsy specimens of lesional skin showed a
very similar pattern characterized by spongiform pustules in the
epidermis with slight acanthosis and dermal edema with a
mixed neutrophilic and lymphocytic inflammatory infiltrate.
Direct immunofluorescence, performed on peripustular
normal skin, was negative in all patients.
Treatment and Course
The first 6 patients were initially treated with cimetidine in
combination with ascorbic acid, achieving improvement of the
clinical picture. Short cycles of both topical and systemic
corticosteroids (clobetasole dipropionate and intravenous
methylprednisolone 1mg/kg per d, respectively) were sub-
sequently used for relapses. The other 9 patients were treated
with both topical and systemic corticosteroids (Table 1). Dap-
sone was added as immunomodulating agent in highly relapsing
Medicine  Volume 94, Number 50, December 2015cases (patients no. 10 and no. 11); in patient no. 10, an
immunosuppressant like cyclosporine and then a biologic like
infliximab were necessary to control disease activity. In the 3
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Marzano et al Medicine  Volume 94, Number 50, December 2015patients with APF triggered by TNF blockers, systemic corticoster-
oids in combination with switching over to other drugs for inflam-
matory bowel diseases (IBD) induced a complete remission ofAPF,
defined as complete absence of the typical pustular lesions. In the 12
patients in which APF was not triggered by drugs, only partial
remission was achieved, defined as significant reduction of the
pustular lesions without a complete clinical healing.
In all patients, systemic antibiotic therapy (amoxicillin
plus clavulanic acid) in combination with antiseptic baths was
given to treat the S aureus superinfection.
Expression Analysis of Cytokines, Chemokines,
and Effector Molecules in Skin Specimens
Cytokine Expression
In lesional skin of the 9 patients with APF compared to 6
normal skin controls, we observed a significant overexpression of
IL-1-beta (median and [interquartile range], 14.35 [7.07–98.96]) vs
3.90 [2.04–5.06]; P¼ 0.005) and of its receptors IL-1RI (3.25
[2.47–6.03] vs 2.08 [1.68–2.54]; P¼ 0.018 and IL-1RII (8.83
[6.01–10.67] vs 4.11 [3.51–6.64]; P¼ 0.034; Figure 2). The proin-
flammatory cytokine TNF-alpha was also overexpressed (3.24
[3.03–4.01] vs 2.56 [2.14–2.76]; P¼ 0.007) as well as its receptors
TNFRI (12.26 [8.67–16.19 vs 4.24 [3.39–7.09]; P¼ 0.010) and
TNFRII (12.26 [8.02–18.95] vs 7.15 [4.64–9.15]; P¼ 0.034;
Figure 2). Finally, we observed an overproduction of IL-17 (3.22
[2.37–5.83] vs 2.20 [1.92–2.51];P¼ 0.045) and its receptor IL-17R
(6.29 [4.65–7.51] vs 4.47 [3.47–5.11]; P¼ 0.034; Figure 2).
L-Selectin Expression
FIGURE 1. Clinical features of amicrobial pustulosis of the folds. Ery
groins (A) and the anogenital region (B) in patient 11. Erythemato
the angle of the mouth (D) in patient 9 and the retroauricular fleThe expression of L-selectin was significantly higher in
lesional skin of the 9 patients with APF than in normal skin
(6.91 [5.47–11.34] vs 1.85 [1.58–3.61]; P¼ 0.001; Figure 2).
4 | www.md-journal.comChemokine Expression
As compared to controls, lesional skin of APF patients
showed overexpression of chemokines promoting neutrophil
transendothelial migration into inflamed tissues, such as IL-8
(5.63 [4.81–25.58] vs 2.48 [2.02–4.05]; P¼ 0.003), CXCL 1/2/
3 (51.98 [11.78–103.21] vs 6.43 [4.43–14.56]; P¼ 0.001),
CXCL 16 (3.76 [2.65–4.73] vs 2.67 [2.06–3.09]; P¼ 0.045)
and RANTES (8.70 [5.14–23.24] vs 3.41 [2.23–5.40];
P¼ 0.034; Figure 3).
MMP and TIMP Expression
In lesional skin of APF patients, we observed a significant
overexpression of molecules involved in tissue damage like
MMP-2 (4.61 [3.65–8.79] vs 2.61 [1.81–3.36]; P¼ 0.010) and
MMP-9 (341.56 [193.16–422.67] vs 17.24 [11.89–70.08];
P¼ 0.003; Figure 4). Overproduction of molecules responsible
for inhibitory signals aimed at attenuating MMP-mediated
inflammation, was also demonstrated: TIMP-1 (54.88
[26.65–203.03] vs 4.07 [3.33–6.26]; P¼ 0.001) and TIMP-2
(116.56 [65.39–170.25] vs 62.89 [25.92–75.09]; P¼ 0.025;
Figure 4).
Siglec 5 and 9 Expression
Siglec 5 (66.70 [20.27–162.20]; P¼ 0.001) and Siglec 9
(54.93 [17.92–75.80]; P¼ 0.001), which carry inhibitory sig-
matous-erosive lesions, sometimes covered by crusts, involving the
ustules of the axilla (C) in patient 7. Erosions with crusts involving
es (E) in patient 8.than in normal skin (4.50 [2.91–8.07] and 8.25 [5.62–10.25],
respectively; Figure 4).DISCUSSION
Here, we reported a large series (15 cases) of patients with
APF, a very rare pustular neutrophilic dermatosis that typically
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. Expression of interleukin-1 (IL-1) beta and its soluble receptors I and II (sIL-1RI and sIL-1RII), tumor necrosis factor (TNF)-alpha
and its soluble receptors I and II (sTNFRI and sTNFRII), interleukin-17 (IL-17) and its soluble receptor (sIL17R), and leukocyte selectin (L-
selectin) in omogenate samples of lesional skin from 9 patients with amicrobial pustulosis of the folds (APF). Six normal subjects (NS)
cyto
Medicine  Volume 94, Number 50, December 2015 Amicrobial Pustulosis of the Folds and Autoinflammationinvolves major and minor skin folds, anogenital area, and scalp,
and has been sometimes reported in association with auto-
served as controls. Numerical values represent signal intensity in a
5th and 95th percentiles (whiskers).immune diseases.2–4,10–15 Interestingly, 3 patients of our series
had IBD and developed a skin reaction manifesting as APF after
treatment with anti-TNF agents given for the intestinal disease.
FIGURE 3. Expression of IL-8 (interleukin 8), RANTES (regulated
on activation, normal T cell expressed and secreted), CXCL 1,2,3
(Chemokine [C-X-C motif] ligand 1,2,3; [C¼ cysteine, X¼ any
amino acid]) and CXCL 16 (Chemokine [C-X-C motif] ligand 16)
in omogenate samples of lesional skin from 9 patients with
amicrobial pustulosis of the folds (APF). Six normal subjects
(NS) served as controls. Numerical values represent signal inten-
sity in a cytokine array assay. Median values, interquartile ranges
(boxes), and 5th and 95th percentiles (whiskers).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.In all 3 patients, APF resolved upon TNF blocker withdrawal
combined with a corticosteroid cycle, strongly suggesting a
triggering role of these drugs. The observation of 3 APF cases
following anti-TNF therapy for IBD, together with a similar 1
reported by Lee et al,16 expands both the clinical context during
which APF may occur and the spectrum of cutaneous compli-
cations related to anti-TNF biologics. It is well known that
neutrophilic dermatoses, particularly PG and SS, are among the
better-recognized extraintestinal manifestations of IBD,17–20
and these 2 groups of disorders have also close pathophysio-
logical links that consists of sharing an important autoinflam-
matory component.7,9,21,22 Pustular reactions represent a
paradoxical event since TNF antagonists are commonly used
in the treatment of psoriasis, including its pustular variant,
which is nowadays considered an autoinflammatory con-
dition23,24 like PG and SS. In our study, another interesting
finding that suggests autoinflammation for APF is that, in 7
patients of our series, although ANA were present in their
serum, there was not an underlying autoimmune/dysimmune
disease. Considering that APF has been reported almost exclu-
sively in women, another noteworthy finding is that 2 patients of
our series were men; in these 2 male patients, the disease
presented with the same clinical picture of female patients.
In 1 patient, extracutaneous involvement, namely lung conso-
lidation resistant to antibiotics but responsive to corticosteroids,
was evident, supporting the view of ‘‘neutrophilic disease.’’6
Concerning APF treatment, we have treated our first 6 patients
(Table 1) with cimetidine in combination with ascorbic acid,
achieving a good response but with a high rate of relapses.
kine array assay. Median values, interquartile ranges (boxes), andSubsequently, we adopted a regimen consisting of topical and
systemic corticosteroids, obtaining not only clinical remission
but also a longer disease-free period. As maintenance therapy,
www.md-journal.com | 5
FIGURE 4. Expression of MMP-2 (matrix metalloproteinase-2), MMP-9, TIMP-1 (tissue inhibitor of metalloproteinase 1), TIMP-2, sialic
acid-binding immunoglobulin-type lectin 5 (Siglec 5), and Siglec 9 in omogenate samples of lesional skin from 9 patients with amicrobial
ntro
5th
Marzano et al Medicine  Volume 94, Number 50, December 2015we used in 2 patients the immunomodulating agent dapsone,
observing a good efficacy and safety profile. Later, 1 of these 2
patients became refractory and was treated initially with the
immunosuppressant cyclosporine and then with the TNF
blocker infliximab with a satisfactory disease control.
In our study, we found an overexpression of IL-1 beta and
its receptors in all the 9 patients evaluated. This could be linked
to a dysregulation of the inflammasome, which is a molecular
platform inducing the activation of caspase 1, an enzyme that
proteolytically cleaves the inactive pro-IL-1 beta to its func-
tionally active isoform, IL-1 beta. IL-1 induces the formation
and release of other proinflammatory cytokines, notably TNF-
alpha and interferon (IFN)-gamma, and chemokines, including
IL-8 and RANTES.25 TNF-alpha, another crucial cytokine in
the inflammatory scenario,26 was overexpressed in our patients
with APF. We also found an upregulation of chemokines,
including IL-8, CXCL 1/2/3, CXCL16, and RANTES, which,
in combination with L-selectin overexpression, are responsible
for neutrophil recruitment and activation. In all patients with
APF, an overexpression of IL-17 was found as well as for its
receptor, supporting the role of this proinflammatory cytokine
in the pathogenesis of neutrophilic dermatoses, as reported in
other immune-mediated disorders.27–29 IL-17 contributes to
neutrophil and monocyte chemotaxis by stimulating the tissue
production of chemokines30 and acting in combination with
other proinflammatory cytokines.31 In addition, IL-17, syner-
gizing with IL-1 and TNF-alpha, increases the production of
MMP-2 and MMP-9.32 The excessive production of MMPs
mainly by neutrophils contributes to tissue damage by destroy-
ing the extracellular matrix and inducing the release of che-
mokines.33 In our study, MMP-9 and to a lesser extent MMP-2
pustulosis of the folds (APF). Six normal subjects (NS) served as co
assay. Median values, interquartile ranges (boxes), and 5th and 9were overexpressed in APF lesional skin, supporting the role of
these gelatinases in the induction of tissue damage. Intriguingly,
we observed an upregulation of TIMP-1 and TIMP-2, which are
6 | www.md-journal.comknown to inhibit the MMP-mediated inflammation. Also the
inhibitory receptors SIGLEC 5 and SIGLEC 9,29 which were
overexpressed in our APF patients, are likely to carry inhibitory
signals dampening inflammation.
The main limitation of our study is the small number of
patients, due to the rarity of APF, which may be, however,
counterbalanced by the wide panel of molecules investigated
and by the clear-cut differences observed. Moreover, 1 could
argue that the ideal controls to evaluate the role of proinflam-
matory cytokines in the pathogenesis of APF would be normal
skin from healthy subjects and normal skin of APF patients.
However, we have decided to choose normal skin adjacent to
noninflammatory lesions of subjects without any immune-
mediated disorder as control to avoid the possible finding of
an overexpression of inflammatory molecules. Another source
of bias could be the location of the biopsy because the skin of
areas different from major and minor folds is not involved in
APF. Testing the normal skin of major and minor folds in APF
patients before the development of the typical pustular lesions
would be very interesting and could be the matter for future
studies aimed at identifying early molecular changes preceding
the onset of the cutaneous manifestations.
As a whole, our data show high values of proinflammatory
cytokines, chemokines, and tissue damage effector molecules,
sometimes associated with a few autoantibodies but without a
clear underlying autoimmune/dysimmune disease, supporting
the autoinflammatory origin of APF. This is in line with an
increasing evidence that indicates clinical and immunological
similarities between autoinflammatory and autoimmune
diseases, giving rise to consider them as a single group of
diseases with a large spectrum of immunologic and clinical
ls. Numerical values represent signal intensity in a cytokine array
percentiles (whiskers).abnormalities. The spectrum includes at one end pure autoin-
flammatory diseases and at the other end pure autoimmune
diseases.34,35
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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